Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2007; 42(2): 122-129
DOI: 10.1055/s-2007-971164
Fachwissen: Topthema: Antibiotikatherapie

© Georg Thieme Verlag Stuttgart · New York

Beatmungsassoziierte Pneumonie und multiresistente bakterielle Erreger

Ventilater-associated pneumonia and multiresistant bacteriaAlexandra Heininger, Klaus Unertl
Further Information

Publication History

Publication Date:
16 February 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die beatmungsassoziierte Pneumonie ist die bedeutendste nosokomiale Infektion in der Intensivmedizin. Eine frühzeitige adäquate Antibiotikatherapie hat höchste Priorität für das Outcome der Patienten; die Frage nach der optimalen diagnostischen Strategie steht dahinter zurück. Die initiale Antibiotikawahl richtet sich danach, ob multiresistente Erreger zu erwarten sind. Im Risikofall ist eine empirische Kombinationsbehandlung indiziert, die vorangegangene Antibiotikabehandlungen und lokale Resistenzmuster berücksichtigt. Die Reevaluation und Deeskalation der Therapie anhand der mikrobiologischen Befunde und die Begrenzung der Therapiedauer auf eine Woche sind entscheidend, um den Einsatz von Breit-spektrum-Antibiotika und die Selektion multiresistenter Erreger einzudämmen.

Summary

Ventilator-associated pneumonia remains the most serious nosocomial infection in critically ill patients. Providing appropriate antibiotic therapy promptly is crucial for successful treatment; whereas the diagnostic approach seems to play a minor role. The empirical antibiotic therapy should be guided by the risk for infections due to multiresistant bacteria. For patients at risk a combination therapy, considering local resistance data and formerly applied antibiotic substances, is recommended. Reevaluation and deescalation of antibiotic therapy based on microbiological culture results and discontinuation of antimicrobial treatment after one week is essential for the control of broadspectrum antibiotic use and antibiotic resistance.

Schlüsselwörter:

beatmungsassoziierte Pneumonie - multiresistente Erreger - Pseudomonas aeruginosa - methicillinresistenter Staphylococcus aureus (MRSA) - Acinetobacter ssp

Key words:

ventilator-associated pneumonia - multiresistant microorganisms - Pseudomonas aeruginosa - methicillin-resistant Staphylococcus aureus (MRSA) - Acinetobacter ssp

Kernaussagen

  • Beatmete Patienten haben ein erheblich höheres Pneumonierisiko als spontan atmende Patienten; das Risiko steigt kumulativ mit der Beatmungsdauer.

  • Das Auftreten einer beatmungsassoziierten Pneumonie wird in erster Linie durch die Intubation begünstigt; entsprechend kann die Pneumoniehäufigkeit durch noninvasive Beatmung gesenkt werden.

  • Weitere sinnvolle Maßnahmen der Pneumonieprävention sind oropharyngeale Dekontamination, Oberkörperhochlagerung und subglottische Sekretabsaugung. Sedativa sollten restriktiv eingesetzt werden, um die Beatmungszeiten und das damit assoziierte Pneumonierisiko möglichst gering zu halten.

  • Ein allgemein anerkannter Goldstandard für die Diagnostik der VAP existiert nicht. Anhand klinischer und radiologischer Zeichen kann die Diagnose nicht eindeutig gestellt werden.

  • Durch bronchoskopische Gewinnung von Bronchialsekret in Kombination mit einer quantitativen mikrobiologischen Untersuchung kann die Diagnose mit hoher Spezifität gestellt werden; die Sensitivität ist allerdings - besonders bei bereits vorangegangener Antibiotikagabe - weit unter 100 %. Wichtig für den Erregernachweis ist, dass Blutkulturen und Proben von respiratorischen Sekreten vor Beginn der Antibiotikabehandlung gewonnen werden.

  • Die mikroskopische Untersuchung von Trachealsekret oder BAL kann Anhaltspunkte für die Wahl der empirischen Antibiotikatherapie geben.

  • Die häufigsten Erreger der VAP sind Pseudomonas aeruginosa, Staphylococcus aureus und Enterobacteriaceae. Wie weit mit multiresistenten Stämmen zu rechnen ist, hängt ab von der Dauer des Krankenhausaufenthalts, vorangegangenen Antibiotikabehandlungen sowie sog. Healthcare assoziierten Faktoren, wie z.B. Dialyse. Eine weitere wichtige Rolle spielt die lokale Prävalenz multiresistenter Isolate in der jeweiligen Intensivstation.

  • Das Outcome der Patienten hängt von einer frühen und gleichzeitig adäquaten empirischen Antibiotikabehandlung ab.

  • Um für einen möglichst hohen Anteil der Patienten noch vor Erhalt der mikrobiologischen Befunde eine wirksame Therapie sicherzustellen, sollte in Fällen, die resistente Erreger erwarten lassen, empirisch mit einer Kombination von zwei pseudomonaswirksamen Substanzen sowie einem MRSA-wirksamen Präparat begonnen werden.

  • Nach Erhalt der mikrobiologischen Befunde sollte eine Reevaluation erfolgen, um die Behandlung entweder anhand des Antibiogramms nachgewiesener Erreger auf Antibiotika mit schmalerem Spektrum zu deeskalieren oder - falls sich der Verdacht auf eine Pneumonie nicht bestätigen lässt - die Therapie zu beenden.

  • Bei gesicherter Pneumonie kann die Dauer der Antibiotikabehandlung auf acht Tage mit einer einzelnen Substanz begrenzt werden; bei Pneumonien mit Pseudomonas aeruginosa ist dieses Vorgehen allerdings umstritten.

Literaturverzeichnis

  • 1 Vincent JL, Bihari DJ, Suter PM. et al. . The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infenction in Intensive Care (EPIC) Study.  JAMA. 1995;  274 639-644
    CrossrefPubMedGoogle Scholar
  • 2 Kollef MH. What is ventilator-associated pneumonia and why is it important?.  Respir Care. 2005;  50 714-721
    PubMedGoogle Scholar
  • 3 Chastre J, Fagon JY. Ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2002;  165 867
    CrossrefPubMedGoogle Scholar
  • 4 Rello J, Ollendorf DA, Oster G. et al. . Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.  Chest. 2002;  122 2115
    CrossrefPubMedGoogle Scholar
  • 5 Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review.  Crit Care Med. 2005;  33 2184-2193
    CrossrefPubMedGoogle Scholar
  • 6 Hugonnet S, Eggiman P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome.  Infect Control Hosp Epidemiol. 2004;  25 1090-1096
    CrossrefPubMedGoogle Scholar
  • 7 Heyland DK, Cook DJ, Griffith L. et al. . The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient.  Am J Respir Crit Care Med. 1999;  159 1249-1256
    CrossrefPubMedGoogle Scholar
  • 8 Bregeon F, Ciais V, Carret. et al. . Is ventilator-associated pneumonia an independent risk factor for death?.  Anesthesiology. 2001;  94 554-560
    CrossrefPubMedGoogle Scholar
  • 9 Rello J. Bench-to-bedside review: therapeutic options and issues in the management of ventilator-associated bacterial pneumonia.  Crit Care. 200;  9 259-265
    PubMedGoogle Scholar
  • 10 Gastmeier P, Sohr D, Geffers C, Behnke M, Rüden H. Mortality risk factors for noso-comial infection in intensive care units: findings from the German nosocomial infection surveillance system (KISS). Infection Control Hosp Epidemiol in press
    Google Scholar
  • 11 American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health-care-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
    CrossrefPubMedGoogle Scholar
  • 12 Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention.  Respir Care. 2005;  50 725-739
    PubMedGoogle Scholar
  • 13 Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A. et al. . Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.  N Engl J Med. 1995;  333 817-821
    CrossrefPubMedGoogle Scholar
  • 14 Hess DR. Noninvasive positive-pressure ventilation and ventilator-associated pneumonia.  Respir Care. 2005;  50 924-929
    PubMedGoogle Scholar
  • 15 Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.  BMJ. 2003;  326 185
    CrossrefPubMedGoogle Scholar
  • 16 Niederman MS. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences.  Semin Respir Infect. 1990;  5 173-184
    PubMedGoogle Scholar
  • 17 Torre FJ De la, Pont T, Ferrer A, Rossello J, Palmar M, Planas M. Pattern of tracheal colonization during mechanical ventilation.  Am J Respir Crit Care Med. 1995;  152 1028-1033
    PubMedGoogle Scholar
  • 18 Ewig S, Torres A, El-Ebiary M, Fabregas N, Hernandez C, Gonzalez J. et al. . Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneu-monia.  Am J Respir Crit Care Med. 1999;  159 188-198
    CrossrefPubMedGoogle Scholar
  • 19 Johanson WG, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with Gram-negative bacilli: the significance of colonization of the respiratory tract.  Ann Intern Med. 1972;  77 701-706
    PubMedGoogle Scholar
  • 20 George DL, Falk PS, Wunderink RG, Leeper KV, Meduri Gu, Steere EL. et al. . Epidemiology of ventilator-associated pneumonia based on protected bronchoscopic sampling.  Am J Respir Crit Care Med. 1998;  158 1839-1847
    PubMedGoogle Scholar
  • 21 Bergmans DCJJ, Bonten MJM, Gaillard CA. et al. . Prevention of ventilator-associated pneumonia by oral decontamination.  Am J Respir Crit Care Med. 2001;  164 382-388
    PubMedGoogle Scholar
  • 22 Abele-Horn M, Dauber A, Bauernfeind A. et al. . Decrease in nosocomial pneumonia in ventilated pateints by selective oropharyngeal decontamination (SOD).  Intensive Care Med. 2007;  23 187
    PubMedGoogle Scholar
  • 23 Riso AJ De, Ladowski JS, Dillon TA, Justice JW, Peterson AC. Chlorhexidine gluconate 0,12 % oral rinse reduces the incidence of total nosocomial espiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 1996
    Google Scholar
  • 24 Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO. Effectiveness of 0,12 % chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery.  Am J Crit Care. 2002;  11 567-570
    PubMedGoogle Scholar
  • 25 Fourrier F, Dubois D, Pronnier P. PIRAD Study Group . Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: a double-blind placebo-controlled multicenter study.  Crit Care Med. 2005;  33 1728-1735
    CrossrefPubMedGoogle Scholar
  • 26 Kollef M, Pittet D, Sanchez M Garcia. Prevention of Pneumonia Study (POPS-1) Trial Group. A randomised double-blind trial of iseganan prevention of ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2006;  173 91-9
    CrossrefPubMedGoogle Scholar
  • 27 Bonten MJ, Bergmann DC, Ambergen AW, Leeuw PW De, Geest S Van der, Stobberingh EE, Gaillard CA. Risk factors for pneumonia and colonization of respiratory tract and stomach in mechanically ventilated ICU patients.  Am J Respir Crit Care Med. 1996;  154 1339-1346
    PubMedGoogle Scholar
  • 28 Krueger WA, Lenhart FP, Neeser G, Et al.. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections. Organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomised, double-blind, placebo-controlled clinical trial.  Am J Respir Crit Care Med. 2002;  166 1029
    CrossrefPubMedGoogle Scholar
  • 29 Jonge E De, Schultz MJ, Spanjaard L. et al. . Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial.  Lancet. 2003;  362 1011
    CrossrefPubMedGoogle Scholar
  • 30 Cal MA De La, Cerda E, Garcia P Hierro, Saene HK van, Gomez-Santos D, Negro E, Lorente JA. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial.  Ann Surg. 2005;  241 424-430
    CrossrefPubMedGoogle Scholar
  • 31 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Diagnose und Therapie der Sepsis. AWMF-Reg.-Nr. 079/001 Entwicklungsstufe 2, Stand 12/05, gültig bis 12/07 leitlinien.net
    Google Scholar
  • 32 Heininger A, Meyer E, Schwab F, Marschal M, Unertl K, Krueger A. Effects of long-term routine use of selective digestive decontamination on antimicrobial resistance.  Intensive Care Medicine. 2006;  32 1569-1576
    CrossrefPubMedGoogle Scholar
  • 33 Chastre J. Conference Summary: Ventilator-associated pneumonia.  Respir Care. 2005;  50 975-983
    PubMedGoogle Scholar
  • 34 Dezfulian C, Shojania K, Collard HR. et al. . Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis.  Am J Med. 2005;  118 11
    CrossrefPubMedGoogle Scholar
  • 35 Cobben NA, Drent M, Jonkers M, Wouters EF, Vaneechoutte M, Stobberingh EE. Outbreak of severe Pseudomonas aeruginosa respiratory infections due to contaminated nebulizers.  J Hosp Infect. 1996;  33 63-70
    CrossrefPubMedGoogle Scholar
  • 36 Srinivasan A, Wolfenden LL, Song X, Mackie K, Hartsell TL, Jones HD. et al. . An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes.  N Engl J Med. 2003;  348 221-227
    CrossrefPubMedGoogle Scholar
  • 37 Struelens MJ, Carlier E, Maes N, Serays E, Quint WG, Belkum A van. Nosocomial colonization and infection with multirsistant Acinetobacter baumanii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting.  J Hosp Infect. 1993;  25 15-32
    CrossrefPubMedGoogle Scholar
  • 38 Unertl K, Heininger A, Unger G. Kommission für Krankenhaushygiene und Infektionsprävention am Robert-Koch-Institut. . Prävention der nosokomialen Pneumonie.  Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2000;  43 302-309
    PubMedGoogle Scholar
  • 39 Tablan OC, Anderson LJ, Besser R. et al. . Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee.  MMWR Recomm Rep. 2004;  53 1
    PubMedGoogle Scholar
  • 40 Needleman J, Buerhaus P, Mattke S, Stewart M, Zelevinsky K. Nurse-staffing levels and the quality of care n hospitals.  N Engl J Med. 2002;  346 1715-1722
    CrossrefPubMedGoogle Scholar
  • 41 Zack JE, Garrison T, Trovillion E, Clinkscale D, Coopersmith CM, Fraser VJ, Kollef MH. Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia.  Crti Care Med. 2002;  30 2407-2412
    CrossrefPubMedGoogle Scholar
  • 42 Torres A, Ewig S. Diagnosing ventilator-associated pneumonia.  N Engl J Med. 2004;  350 433-435
    CrossrefPubMedGoogle Scholar
  • 43 Heininger A, Krueger WA, Doring G, Unertl K. Ventilator-associated pneumonia.  Curr Opin Anaesthesiol. 2002;  15 153-159
    CrossrefPubMedGoogle Scholar
  • 44 Porzecanski I, Bowton DL. Diagnosis and treatment of ventilator-associated pneumonia.  Chest. 2006;  130 597-604
    CrossrefPubMedGoogle Scholar
  • 45 Ostendorf U, Ewig S, Torres A. Nosocomial pneumonia.  Curr Opin Infet Dis. 2006;  19 327-338
    PubMedGoogle Scholar
  • 46 Fabregas N, Ewig S, Torres A. et al. . Clinical diagnosis of ventilator-associated pneumonia revisisted: comparative validation using immediate postmortem lung biopsies.  Thorax. 1999;  54 867
    CrossrefPubMedGoogle Scholar
  • 47 Niederman MS. The clinical diagnosis of ventilator-associated pneumonia.  Respir Care. 2005;  50 788-796
    PubMedGoogle Scholar
  • 48 Chastre J, Combes A, Luyt C-E. The invasive (quantitative) diagnosis of ventilator-associated pneumonia.  Respir Care. 2005;  50 797-807
    PubMedGoogle Scholar
  • 49 Torres A, El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia.  Chest. 2000;  117 S198-S202
    CrossrefPubMedGoogle Scholar
  • 50 Timsit JF, cheval C, Gachot B. et al. . Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluid in the initial antibiotic therapy of suspected ventilator-associated pneumonia.  Intensive Care Med. 2001;  27 640-647
    CrossrefPubMedGoogle Scholar
  • 51 Brun-Buisson C, Fartoukh M, Lechapt E. et al. . Contribution of blinded protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated pneumonia.  Chest. 2005;  128 2706-2713
    CrossrefPubMedGoogle Scholar
  • 52 Fagon J-Y, Chastre J, Wolff M. et al. . Invasive and non-invasive strategies for management of suspected ventilator-associated pneumonia.  Ann Intern Med. 2000;  132 621-630
    PubMedGoogle Scholar
  • 53 Sanchez M Nieto, Torres A, Garcia-Cordoba F. et al. . Impact of invasive and noninvasive quantiative culture sampling on outcome of ventilator-associated pneumonia.  Am J Respir Crit Care med. 1998;  157 371-376
    PubMedGoogle Scholar
  • 54 Ruiz M, Torres A, Ewig S. et al. . Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2000;  162 199-125
    PubMedGoogle Scholar
  • 55 Violan JS, Fernande JA, Benitez AB. et al. . Impact of quantitative diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia.  Crit Care med. 2000;  28 2737-2741
    CrossrefPubMedGoogle Scholar
  • 56 Shorr A, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis.  Crit Care Med. 2005;  33 46
    CrossrefPubMedGoogle Scholar
  • 57 Blot F, Baynard B, Chachaty E, Tancrede C, Antoun S, Nitenberg G. Value of Gram stain examination of lower respiratory tract secretions for early diagnosis of nosocomial pneumonia.  Am J Respir Crit Care Med. 2000;  162 1731-1737
    PubMedGoogle Scholar
  • 58 Veinstein A, Brun-Buisson C, Derrode N, Alvarez A, Pinsard M, Robert R, Blot F. Validation of an algorithm based on direct examination of specimens in suspected ventilator-associated pneumonia.  Intensive Care Med. 2006;  32 676-683
    CrossrefPubMedGoogle Scholar
  • 59 Vidaur L, Sirgo G, Rodriguez AH, Rello J. Clinical approach to the patient with suspected ventilator-associated pneumonia.  Respir Care. 2005;  50 965-974
    PubMedGoogle Scholar
  • 60 Lynch J. Hospital-acquired pneumonia: risk factors, microbiology and treatment. Chest 2001: S373-S384
    Google Scholar
  • 61 Park DR. The microbiology of ventilator-associated pneumonia.  Respir Care. 2005;  50 742-763
    PubMedGoogle Scholar
  • 62 Gastmeier P. Surveillance nosokomialer Infektionen: Schwerpunkt Intensivmedizin.  www.p-e-g.org/arhicv_tmp/bad_honnef_symposiuim2006/ga
    Google Scholar
  • 63 Combes A, Figliolini C, Trouillet JL, Kassis N, Wolff M, Gibert C. et al. . Incidence and outcome of polymicrobial ventilator-associated pneumonia.  Chest. 2002;  121 1618-1623
    CrossrefPubMedGoogle Scholar
  • 64 Craven DE. Epidemiology of ventilator-associated pneumonia.  Chest. 2000;  117 S186-S187
    CrossrefPubMedGoogle Scholar
  • 65 Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G. Ealrly onset-pneumonia: a multicenter study in intensive care units.  Intensive Care Med. 1987;  13 342-346
    PubMedGoogle Scholar
  • 66 Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset versus late-onset nosocomial pneumonia (NP) in the ICU setting.  Chest. 2000;  117 1434-1442
    CrossrefPubMedGoogle Scholar
  • 67 Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria.  Intensive Care Med. 2005;  31 1488-1494
    CrossrefPubMedGoogle Scholar
  • 68 Jacoby GA. Epidemiology of extended-spectrum beta-lactamases.  Clin Infect Dis. 1998;  27 81
    PubMedGoogle Scholar
  • 69 Pena C, Pujol M, Ardanuy C. et al. . Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.  Antimicrob Agents Chemother. 1998;  42 53
    PubMedGoogle Scholar
  • 70 Champs C De, Rouby D, Guelon D. et al. . A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1(TEM-3) beta-lactamase.  J Hosp Infect. 1991;  18 5
    PubMedGoogle Scholar
  • 71 Schippa DA, Hayden MK, Mathushek MG. et al. . Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.  J Infect Dis. 1996;  174 529
    PubMedGoogle Scholar
  • 72 Lucet JC, Chevret S, Decre D. et al. . Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition.  Clind Infect Dis. 1996;  22 430
    PubMedGoogle Scholar
  • 73 Jacoby GA, Munoz-Price LS. The new beata-lactamases.  N Engl J Med. 2005;  352 380
    CrossrefPubMedGoogle Scholar
  • 74 Rello J, Allegri C, Rodriguez A, Vidaur L, Sirgo G, Gomez F, Agbaht K, Pobo A, Diaz E. Risk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure.  Anaesthesiology. 2006;  105 709-714
    CrossrefPubMedGoogle Scholar
  • 75 Babcock HM, Zack JE, Garrison T, Trovillion E, Kollef MH, Fraser VJ. Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location.  Infect Control Hosp Epidemiology. 2003;  24 853-858
    CrossrefPubMedGoogle Scholar
  • 76 Park DR. Antimicrobial treatment of ventilator-associated pneumonia.  Resp Care. 2005;  50 932-952
    PubMedGoogle Scholar
  • 77 Dellinger RP, Carlet J, Masur H. et al. . Surviving sepsis campaign for management of severe sepsis and septic shock.  Crit Care Med. 2004;  32 858-872
    CrossrefPubMedGoogle Scholar
  • 78 Kollef MH, Ward S. The influence of mini-BAL cultutes on patients outcomes: implications for the antibiotic management of ventilator-associated pneumonia.  Chest. 1998;  113 412-420
    CrossrefPubMedGoogle Scholar
  • 79 Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.  Clin Infect Dis. 2000;  31 S131-S138
    CrossrefPubMedGoogle Scholar
  • 80 Dupont H, Mentec H, Sollet JP. et al. . Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia.  Intensive Care Med. 2001;  27 355-362
    CrossrefPubMedGoogle Scholar
  • 81 Luna CM, Vujacich P, Niederman MS. et al. . Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.  Chest. 2007;  111 676-685
    PubMedGoogle Scholar
  • 82 Eggimann P, Revelly J-P. Should antibiotic combinations be used to treat ventilator-associated pneumonia?.  Semin Respir Crit Care Med. 2006;  27 68-81
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Micek ST, Lloyd AE, Ritchie DJ. et al. . Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.  Antimicrob agents chemother. 2005;  49 1306-1311
    CrossrefPubMedGoogle Scholar
  • 84 Michel F, Franceschini B, Berger P. et al. . Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures.  Chest. 2005;  127 589-597
    CrossrefPubMedGoogle Scholar
  • 85 Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, Vogelaers DP, Decruyenaere JM, Colardyn FA. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit.  Crit Care Med. 2006;  34 653-659
    CrossrefPubMedGoogle Scholar
  • 86 Singh N, Rogers P, Watwood CW. et al. . Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.  Am J Respir Crit Care Med. 2000;  162 505-511
    CrossrefPubMedGoogle Scholar
  • 87 Chastre J, Wolff M, Fagon JY. et al. . Comparison of 8 vs. 14 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588
    CrossrefPubMedGoogle Scholar
  • 88 Paul M, Silbiger I, Grozinsky S. et al. . Beta lactam antibiotic monotherapy vs. beta lactamaminoglycoside antibiotic combination therapy for sepsis.  Cochrane Database Syst Rev. 2006;  25
    PubMedGoogle Scholar
  • 89 Bliziotis IA, Samonis G, Vardakas KZ. et al. . Effect of aminoglycoside and beta-lactam combination therapy vs. beta-lacltam monotherapy on the emrgence of antimicrobial resistance: A meta-analysis of randomized controlled trials.  Clin Infect Dis. 2005;  41 149-158
    CrossrefPubMedGoogle Scholar
  • 90 Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta-lactam monotherapy versus beta-lacta-aminoglycoside combination theapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials.  BMJ. 2004;  328 668-672
    CrossrefPubMedGoogle Scholar
  • 91 Cornetta A, Baumgartner JD, Lew D. et al. . Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.  Antimicrob Agents Chemother. 1994;  38 1309-1313
    CrossrefPubMedGoogle Scholar
  • 92 Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.  Lancet Infect Dis. 2004;  4 519-527
    CrossrefPubMedGoogle Scholar
  • 93 Meyer E, Jonas D, Schwab F, Gastmeier P, Rüden H, Daschner FD. SARI: Surveillance der Antibiotikaanwendung und bakteriellen Resistenzentwicklung auf deutschen Intensivstationen.  Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2004;  47 345-351
    CrossrefPubMedGoogle Scholar
  • 94 Kollef MH. Gram-negative bacterial resistance: evolving patterns and treatment paradigms.  Clin Infect Dis. 2005;  40 S85-S88
    PubMedGoogle Scholar
  • 95 Nordmann P, Poirel L. Emerging carabapenemases in Gram-negative anaerobes.  Clin Microbiol Infect. 2002;  8 321-331
    CrossrefPubMedGoogle Scholar
  • 96 Borgmann S, Wolz C, Grobner S, Autenrieth IB, Heeg P, Goerke C, Muller K, Kyme P, Marschal M. Metallo-beta-lactamase expressing multi-resistant Acinetobacter baumanii transmitted in the operation area.  J Hosp Infect. 2004;  57 308-315
    CrossrefPubMedGoogle Scholar
  • 97 Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and impenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia.  Clin Infect Dis. 2002;  34 1425-1430
    CrossrefPubMedGoogle Scholar
  • 98 Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline against Acinetobacter baumanii strains, including those resistant to imipenem.  Antimicrob Agents Chemother. 2004;  48 4479-4481
    CrossrefPubMedGoogle Scholar
  • 99 Bonomo R, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.  Clin Infect Dis. 2006;  43 S49-S56
    CrossrefPubMedGoogle Scholar
  • 100 Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Aruda EA. et al. . Intravenous colistin as therapy for nosocomial infetions caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanii.  Clin Infect Dis. 1999;  28 1008-1011
    PubMedGoogle Scholar
  • 101 Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopulos S, Falagas ME. Colistin treatment in patients with icu-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.  Clin Microbiol Infect. 2005;  11 115-121
    CrossrefPubMedGoogle Scholar
  • 102 Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.  Clin Infect Dis. 2006;  43 S95-S99
    CrossrefPubMedGoogle Scholar
  • 103 Murray CK, Hospenthal DR. Treatment of multidrug resistant Acinetobacter.  Curr Opin Infect Dis. 2005;  18 502-506
    PubMedGoogle Scholar
  • 104 Döring G, Conway SP, Heijerman HGM. et al. . Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.  Eur Respir J. 2000;  16 749-767
    CrossrefPubMedGoogle Scholar
  • 105 Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M. et al. . Eradication of endotracheal tube biofilm by nebulised gentamicin.  Intensive Care Med. 2002;  28 426-431
    CrossrefPubMedGoogle Scholar
  • 106 Hamer DH. Treatment of nosocomial pneumonia and tracheobrochitis caused by mul-tidrug-resistant Pseudomonas aeruginosa with aerosolised colistin.  Am J Respir Crit Care Med. 2000;  162 328-330
    CrossrefPubMedGoogle Scholar
  • 107 Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis.  Crit Care. 2005;  9 53-59
    PubMedGoogle Scholar
  • 108 Kwa ALH, Loh CS, Low JGH, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumanii and Pseudomonas aeruginosa.  Clin Infect Dis. 2005;  41 754-757
    CrossrefPubMedGoogle Scholar
  • 109 Kollef MH. Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.  Eur J Clin Microbiol Infect Dis. 2005;  24 794-803
    PubMedGoogle Scholar
  • 110 Fagon J, Patrick H, Haas DW. et al. . Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin.  Am J Respir Crit Care Med. 2000;  161 753
    CrossrefPubMedGoogle Scholar
  • 111 Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2003;  124 1789-1797
    CrossrefPubMedGoogle Scholar
  • 112 Byl B, Jacobs F, Wallemacq P. et al. . Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion.  Antimicrob Agents Chemother. 2003;  47 2015-2017
    CrossrefPubMedGoogle Scholar
  • 113 Lamer C, Beco V de, Soler P. et al. . Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.  Antimicrob Agents Chemother. 1993;  37 281-286
    PubMedGoogle Scholar
  • 114 Shorr AF, Duh MS, Kelly KM, Kollef MH. Red blood cell transfusion and ventilator-associated pneumonia: a potential link?.  Crit Care Med. 2004;  32 666-674
    CrossrefPubMedGoogle Scholar
  • 115 Bornstain C, Azoulay E, Lassence A De. et al. . Sedation, sucralfate, and antibiotic use are potneital means for protection against early-onset ventilator-associated pneumonia.  Clin Infect Dis. 2004;  38 1401-1408
    CrossrefPubMedGoogle Scholar
  • 116 Pawar M, Mehta Y, Khurana P. et al. . Ventilator-associated pneumonia: incidence, risk factors, outcome, and microbiology.  J Cardiothorac Vasc Anesth. 2003;  31 1312-1317
    PubMedGoogle Scholar
  • 117 Kobashi Y, Matshushima T. Clinical analysis of patients requring long-term mechanical ventilaton over three months: ventilator-associated pneumonia as a primary complication.  Intern Med. 2003;  43 25-32
    PubMedGoogle Scholar
  • 118 Alp E, Guven M, Yildiz O. et al. . Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study.  Ann Clin Microbiol Antimicrob. 2004;  3 17
    CrossrefPubMedGoogle Scholar
  • 119 Bullock TK, Waltrip TJ, Price SA, Galndiuk S. A retrospective study of nosocomial pneumonia in postoperative patients shows a higher mortality rate in patients receiving nasogastgric tube feeding.  Am Surg. 2004;  70 822-826
    PubMedGoogle Scholar
  • 120 Erbay RH, Yalcin AN, Zencir M. et al. . Costs and risk factors for ventilator-associated pneumonia in a Turkish University Hospital`s Intensive Care Unit: a case-control study.  BMC Pulm Med. 2004;  4 3
    CrossrefPubMedGoogle Scholar
  • 121 Warren DK, Shukla SJ, Olsen MA. et al. . Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in asuburban medical center.  Crit Care Med. 2003;  31 1312-1317
    CrossrefPubMedGoogle Scholar
  • 122 ElSolh AA, Bhat A, Gunen H, Berbary E. Extubation failure in the elderly.  Respir Med. 2004;  98 661-668
    PubMedGoogle Scholar
  • 123 Almuneef M, Memish ZA, Balkhy HH. et al. . Ventilator-associated pneumonia in a pediatric intensive care unit in Saudi Arabia: in a 30-month prospective surveillance.  Infect Control Hosp Epidemiol. 2004;  25 753-758
    CrossrefPubMedGoogle Scholar
  • 124 Mukhopadhyay C, Bhargava A, Ayyagari A. Role of mechanical ventilation and development of multidrug resistant organisms in hospital acquired pneumonia.  Indian J Med Res. 2003;  118 229-235
    PubMedGoogle Scholar
  • 125 Sirvent JM, Torres A, Vidaur L. et al. . Tracheal colonisation within 24 h of intubation in patients with head trauma: risk factor for developing early-onset ventilator-associated pneumonia.  Intensive Care Med. 2000;  26 1369-1372
    PubMedGoogle Scholar

Dr. med. Alexandra Heininger
Prof. Dr. med. Klaus Unertl

Email: alexandra.heininger@med.uni-tuebingen.de

Email: klaus.unertl@med.uni-tuebingen.de

      >